Amylin Sucks Customer Reviews and Feedback
Amylin Pharmaceuticals was a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin (pramlintide acetate), Byetta (exenatide), and Bydureon (exenatide extended-release).
Back on July 3, 2012, Amylin was Accused of Withholding Information from FDA, this content reported in a piece posted in FLOOD LAW GROUP:
Amylin Pharmaceuticals, a San Diego-based drug manufacturer, has recently been accused of failing to disclose essential safety information regarding a new diabetes drug in an effort to get the drug approved by the U.S. Food and Drug Administration (FDA), according to a recently published memo written by Mark Parks, an FDA director. Parks’ memo alleges that Amylin, when submitting Bydureon® for FDA approval in May 2009, asked the FDA to rely on safety information associated with Byetta®, a similar diabetes medication approved by the FDA in 2005. The company allegedly withheld information regarding possible heart-related side effects linked to Byetta®. Byetta® and Bydureon® are both injectable medications that are intended to help those with Type 2 diabetes control their blood sugar levels. The active ingredient in both of these drugs is exenatide. Both drugs are typically prescribed in combination with exercise and a healthy diet. The difference between these drugs is Byetta® is a fast-acting medication that requires patients to receive two injections per day and Bydureon® is a long-acting, slow-release medication that only requires patients to receive one injection per week. These diabetes drugs should not be used in conjunction with each other, nor should they be taken to manage Type 1 diabetes. Parks’ memo, which brings to light allegations that Amylin may have acted less than transparent and ethical in its efforts to get Bydureon® approved by the FDA, was not published until after the drug received FDA approval in January 2012. Its publication by the FDA has led many of the company’s investors – as well as some of its potential acquirers – to question Amylin’s practices, which has had ripple effects on the company’s stock prices.
QA (Former Employee) says"Lack of opportunities to advance. Promotions are based on friendships not on merit.good work life balancemanagement, health insurance"
ADMINISTRATIVE ASSISTANT (Former Employee) says"I was a temporary administrative assistant while there, but I enjoyed working there. I assisted the Marketing department and was able to learn new skills while I was there. Although the job was temporary I learned a lot there and it helped me with my next position.Good companyN/a"
Diabetes Sales Specialist (Current Employee) says"Amylin is a great company with good people and good products that help patients."
Senior Developer (Former Employee) says"When I started in 2001, we were a small, sleek research focused company, and it was awesome! But success was our downfall - after we brought out 2 new, first in calls, drugs, the company changed drastically, focusing solely on sales. Too many sales people, VPs and lawyers, not enough scientists. The BMS acquisition was inevitable.The people - who unfortunately were laid off.Executive Managment."
District Sales Manager (Former Employee) says"A typical day at work involved working in the field with sales representatives calling on customers. Sales calls began with a thorough review of the market, managed care status of Amylin products, as well as prescriber needs. Situational leadership utilized to help set expectations of sales calls as well as discuss success and/or future development.Sales people want to be developed. They want to provide their customers with the latest information and to make the time they spend with their customers relevant to the customer and the patients they serve.Management at Amylin was focused on sales attainment. Situational Leadership was utilized throughout the entire company.My co-workers at Amylin were focused on sales attainment and people development. My management team consisted of high achievers who were focused on hitting sales goals while also providing positive coaching to their teams for individual and team development.The hardest part of my job was the travel. I covered 8 states and was away from home 3-4 nights per week. Time management was a key focus for me to be able to work with my team and address the business needs of the team at the same time.The most enjoyable part of my job was celebrating the successes of the individuals on my team. Jointly establishing goals and seeing the members of my team hit or exceed their goals was a key factor in the enjoyment of my job.small company allowed for interaction at all levels and departmentscompany was sold in august of 2011"
Quality Control Analyst, Bioassay Group (Contract) says"The staff at Amylin are very experienced. The management is professional.Management goodNo advancement"
Garou Recruiter BLM says"@ThePrimogen I can never NOT recommend the b&w Werewolf in London if for nothing else one of my favorite comedy duo… https://t.co/VUsEI2sRJX"
angel says"online classes = rollercoaster of emotions ?"
angel says"@_haeinn I SMELL CINNAMON BUNS HMM"
In The News
Xconomy reports"Amylin Strikes $1 Billion Deal with Takeda to Co-Develop Weight Loss Drugs"
Forbes reports"Lilly And Amylin End Their Bad Marriage"
Motley Fool reports"Novo Nordisk A/S (NVO) Q2 2020 Earnings Call Transcript"
The Motley Fool reports"How Big Can This $8 Billion-Plus Diabetes Drug Class Get?"